New drug cocktail targets tough pancreatic cancer
NCT ID NCT06773130
First seen Nov 17, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs, HRS-4642 and nimotuzumab, in 20 adults with advanced pancreatic cancer that has come back or spread. The goal is to see if the combo is safe and can shrink tumors or slow the disease. This is an early-stage trial, so it focuses on finding the right dose and checking for any benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.